Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 11.02B -52.0% |
| Revenue (ttm) | 741.90M +64.5% |
| Net Income | -1.70B |
| EPS | -4.56 |
| Shares Out | 367.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,449,200 |
| Open | 30.34 |
| Previous Close | 29.86 |
| Day's Range | 29.82 - 30.78 |
| 52-Week Range | 25.80 - 69.10 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 72.19 (+140.96%) |
| Est. Earnings | Nov 19, 2026 |
About HKG:6855
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2025, HKG:6855's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for 6855 stock is "Strong Buy." The 12-month stock price target is $72.19, which is an increase of 140.96% from the latest price.
News
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the disco...
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharm...
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the disco...
Ascentage Pharma initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Ascentage Pharma (AAPG) with an Outperform rating. Ascentage remains under the radar to most investors who focus on hematology, and the firm…
Ascentage Pharma initiated with a Buy at Citi
Citi initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $46 price target The firm says the company is transitioning into a global hematology-oncology enterprise. Ascentage’s GLORA-4 m...
Ascentage Pharma initiated with an Outperform at Citizens
Citizens initiated coverage of Ascentage Pharma (AAPG) with an Outperform rating and $35 price target Ascentage is a multinational biotechnology company focused on targeted therapies in oncology, the ...
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading v...
Ascentage Pharma price target lowered to $33 from $46 at JPMorgan
JPMorgan lowered the firm’s price target on Ascentage Pharma (AAPG) to $33 from $46 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first…
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looki...
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biophar...
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began buil...
Ascentage Pharma Group International Earnings Call Transcript: H1 2026
Revenue grew 29% year-over-year to $44.5M, driven by product sales and expanding global trials. Cash runway extends through 2027, with multiple NDA filings expected next year. Key assets show strong differentiation and progress in both China and global markets.
Ascentage Pharma Group International Earnings release: H1 2026
Ascentage Pharma Group International released its H1 2026 earnings on August 20, 2026, summarizing the period's financial results.
Ascentage Pharma Group International Slides: H1 2026
Ascentage Pharma Group International has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 20, 2026.
Ascentage Pharma Group International Quarterly report: H1 2026
Ascentage Pharma Group International has published its H1 2026 quarterly earnings report on August 20, 2026.
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointment...
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharm...
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in the first paragraph of the release, the time should be...
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharm...
Ascentage Pharma appoints Miyara as CBO, Ziegler as CCO
Ascentage Pharma (AAPG) Group announced the appointment of Faical Miyara, PhD, as Chief Business Officer, CBO, responsible for the Company’s global business development, and Jim Ziegler as Chief Comme...
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the disco...
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en...
Ascentage Pharma files to sell American Depositary Shares, no amount given
06:04 EDT Ascentage Pharma (AAPG) files to sell American Depositary Shares, no amount given
Ascentage Pharma assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Ascentage Pharma (AAPG) with an Outperform rating and $45 price target The firm notes Ascentage recently gave two oral presentations on olverembatinib at ASCO, as well…
Ascentage Pharma announces clinical updates from EHA2026
Ascentage Pharma (AAPG) announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: “Efficacy of Olveremb...